EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
1 hedge funds and large institutions have $0 invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2016 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
100% less capital invested
Capital invested by funds: $44K → $0 (-$44K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$44K |
EPRS Hedge Fund Activity: Q4 2016 in Review
1 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q4 2016, worth a combined $0 — down 100% from $44K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EPRS and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was TPG Group Holdings (SBS) Advisors, exiting entirely with an estimated $44K sold.
- 1 institutional investor held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q4 2016, down from 3 in Q3 2016.
- Funds reported $0 of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q4 2016, down 100% quarter-over-quarter.
- 0 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q4 2016 and 2 closed out, a net change of -2 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q4 2016 was TPG Group Holdings (SBS) Advisors, an estimated $44K sold.
Based on aggregated 13F filings for Q4 2016.